Document is current
Any future updates will be listed below
-
Authors
Waks, Adrienne G.
Fu, Jingxin https://orcid.org/0000-0002-4028-3661
Chu, Xiangying https://orcid.org/0009-0000-3474-3804
Binboga Kurt, Busem
Li, Tianyu
Kuntz, Thomas M.
Shen, Yizhuo
Yang, David https://orcid.org/0000-0002-5146-218X
Meli, Kevin
Reardon, Brendan https://orcid.org/0000-0002-1716-5720
Park, Jihye
Partridge, Ann https://orcid.org/0000-0002-4722-4824
Abravanel, Daniel https://orcid.org/0000-0002-0129-1618
Jeselsohn, Rinath https://orcid.org/0000-0001-7996-7529
Wrabel, Eileen
Alberti, Jillian
DiLullo, Molly
Chen, Serenity
Mohammed-Abreu, Ayesha
Sun, Xiaopeng
Balko, Justin M. https://orcid.org/0000-0002-4263-5974
Kleijn, Miranda
Audeh, William
Morgan, Xochitl C.
Krop, Ian E. https://orcid.org/0000-0002-6380-5944
Tayob, Nabihah
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
Mittendorf, Elizabeth A.
Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
- License Information
-
More Information
Article History
Received: 2 October 2024
Accepted: 11 November 2025
First Online: 28 November 2025
Competing interests
: A.G.W. reports consulting or advisory roles for AstraZeneca and AMBRX; speaker’s honoraria from AstraZeneca; and research support (to institution) from Genentech, Gilead, Macrogenics, and Merck. J.B. reports research support from Genentech/Roche and Incyte Corporation; has received advisory board payments from AstraZeneca, Eli Lilly, and Mallinckrodt; and is an inventor on patents regarding immunotherapy targets and biomarkers in cancer. M.K. and W.A. are employees of Agendia. B.R. reports having institutional patents filed on methods for clinical interpretation. E.A.M. reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, and Merck; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. S.M.T. reports consulting or advisory roles for Novartis, Pfizer/SeaGen, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Bristol Myers Squibb/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Jazz Pharmaceuticals, Natera, Tango Therapeutics, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Launch Therapeutics, Zuellig Pharma, Johnson&Johnson/Ambrx, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summit Therapeutics, Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, Olema Pharmaceuticals, Tempus, and Boundless Bio; research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, AstraZeneca, NanoString Technologies, Gilead, SeaGen, OncoPep, Daiichi Sankyo, Menarini/Stemline, Jazz Pharmaceuticals, and Olema Pharmaceuticals; and travel support from Lilly, Gilead, Jazz Pharmaceuticals, Pfizer, Arvinas, and Roche. The remaining authors declare no competing interests.
